Applied Therapeutics Inc (APLT)

A. Company Overview

Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company that specializes in the development of novel therapeutic candidates targeting validated molecular pathways for diseases characterized by significant unmet medical needs. Founded in 2016, the company is primarily focused on leveraging advancements in drug design to create effective and safe treatments by addressing known molecular targets that have historically posed challenges regarding efficacy and tolerability.

The company’s strategic approach involves utilizing established scientific knowledge to develop innovative drug candidates. This focus is directed at improving drug properties via biomarker utilization and optimizing regulatory pathways for expedited development. Currently, Applied Therapeutics is publicly traded and is actively conducting clinical trials for its leading product candidates.

B. Product Pipeline

Aldose Reductase Inhibitors (ARIs)

The core of Applied Therapeutics' development pipeline revolves around Aldose Reductase (AR), an enzyme crucial in diabetic complications and other diseases. The company has a robust portfolio of AR inhibitors, specifically designed to target and modulate the activity of this enzyme, which is implicated in the pathological processes of various conditions, including diabetic complications and rare metabolic disorders.

AT-007 (Govorestat)

AT-007 is a prominent Aldose Reductase inhibitor under development for the treatment of rare metabolic diseases, specifically Galactosemia and Sorbitol Dehydrogenase Deficiency (SORD Deficiency).

Galactosemia

Galactosemia is a genetic disorder characterized by the inability to metabolize galactose properly, leading to the accumulation of toxic metabolites, notably galactitol, which has damaging effects on various tissues including the CNS and peripheral nerves. AT-007 has received orphan drug designation and pediatric rare disease designation from the FDA, reflecting its potential significance in treating these conditions. Clinical trials have demonstrated substantial reductions in plasma galactitol levels in both adult and pediatric patients, with the therapy correlating with improvements in clinical outcomes and quality of life.

In December 2023, Applied Therapeutics submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) and a New Drug Application (NDA) to the U.S. FDA for AT-007, which has subsequently been granted Priority Review status.

SORD Deficiency

SORD Deficiency leads to the accumulation of sorbitol, resulting in progressive neuropathy and complications akin to Charcot-Marie-Tooth diseases. Preclinical studies utilizing AT-007 showcased significant reduction in sorbitol levels in patient-derived fibroblasts. The ongoing Phase 2/3 INSPIRE trial is evaluating the efficacy of AT-007 in SORD Deficiency patients, with interim results indicating promising outcomes in reducing sorbitol levels and improving functional measures over time.

Other Rare Diseases

Additionally, there are plans to advance clinical trials for AT-007 in other pediatric conditions such as PMM2-CDG, a glycosylation disorder with implications for cognitive and motor functions. Early preclinical data exhibits AT-007’s capability to enhance enzyme activity associated with the condition, providing a potential therapeutic avenue for affected children.

AT-001 (Caficrestat)

AT-001 is directed towards diabetic cardiomyopathy (DbCM), a serious complication of diabetes resulting in cardiac dysfunction. Following the completion of a Phase 1/2 clinical trial, indicated results show that AT-001 can stabilize cardiac functional capacity in diabetic patients over extensive treatment periods.

Initiated in 2019, the Phase 3 registrational trial ARISE-HF evaluates the drug's efficacy in enhancing exercise capacity. The latest trial results show a trend towards stabilization of cardiac function in patients treated with AT-001 as opposed to those receiving placebo, warranting further study along with the integration into broader trials measuring functional capacity in diabetic populations.

AT-003

Designed to treat diabetic retinopathy (DR), AT-003 aims to leverage its unique formulation to achieve significant retinal permeability and therapeutic effects. Current methodologies for handling DR are limited and mostly reliant on invasive techniques. The introduction of AT-003 may represent a more accessible treatment paradigm for this common complication of diabetes.

Preclinical Development

Pending results from preclinical studies indicate that the formulation shows potential in reducing damage associated with DR, thus promising a favorable profile leading into human clinical trials focused on establishing safety and efficacy.

Discontinued Programs

AT-104, an earlier-stage dual selective PI3K inhibitor program, has been discontinued due to shifts in regulatory landscapes impacting the development of PI3K inhibitors and associated safety concerns, highlighting the dynamic nature of biopharmaceutical development and the company's agile response to external pressures.

C. Business Model and Collaborations

Applied Therapeutics actively seeks collaborations to bolster its development and commercialization efforts. Notably, a partnership with Advanz Pharma has been established for the European commercialization of AT-007, which allows leverage of financial resources and marketing expertise to facilitate market penetration and revenue generation.

The company’s business model relies heavily on pipeline development, tackling diseases with significant unmet needs while also exploring additional collaborative opportunities to enhance its therapeutic arsenal.

D. Financial Overview

Since its inception, Applied Therapeutics has faced substantial operating losses, reflective of typical trends in biopharmaceutical development where initial capital is consumed largely through research and clinical trial expenses with no product revenue until successful commercialization occurs. For the year ended December 31, 2023, the company reported a net loss of $119.8 million and an accumulated deficit of $468.6 million, indicating continuing developmental expenditures aligned with advancing its clinical candidates.

Well-timed capital raises show a structured approach to funding, with public offerings and private placements helping to sustain operations while pursuing FDA approvals. The company has displayed strategic management of financial resources to support extended research and development activities, with significant cash reserves reported as of late 2023.

E. Management Team

Guided by a team of seasoned professionals with expansive expertise in pharmaceuticals, biopharmaceuticals, and clinical research, Applied Therapeutics is driven by leadership committed to innovative drug development. This encompasses a blend of business strategists and scientific authorities working collaboratively to shorten drug development timelines and elevate clinical success rates.